TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms…
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms…
Toronto, Ontario–(Newsfile Corp. – December 28, 2022) – SuperBuzz Inc. (TSXV: SPZ) (“SuperBuzz” or the…
Veteran PM Tony Bancroft to Lead Team GREENWICH, Conn.–(BUSINESS WIRE)–Gabelli Funds (“GAMCO”) (OTCQX: GAMI) announced…
BitNile still intends to distribute to its stockholders 140 million shares and warrants to purchase…
Fortinet’s Wired and Wireless LAN Portfolio Converges Networking and Security to Help Customers Embrace Digital…
SAN JOSE, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) — Innovation Minds, the leading innovation-based employee…
New York, New York–(Newsfile Corp. – December 28, 2022) – On December 17, 2022, Dentons,…
Geneva, Switzerland, Dec 28, 2022 – (ACN Newswire) – DCM Swiss (Digital Content Marketplace, a…
9 routes and 300 systems added in 2022, making Hayden AI the US leader in…
Finance Education Available on BFine.org COLUMBIA, S.C.–(BUSINESS WIRE)–#bankrtupcy–Many New Year’s resolutions revolve around getting finances…
Hall to Drive Operational Performance, Strategic Growth Initiatives, and M&A WALNUT CREEK, Calif.–(BUSINESS WIRE)–#growth–Please replace…
Silicon Valley’s leading Design Engineer event is set to bring together thousands of engineers, across…
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–#cfo—Planet DDS, the leading provider of cloud-based dental software, is pleased to…
Promotion to SVP, Global Sales comes as Odaseva experiences a year of record growth SYDNEY,…
LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Company engaged a leading clinical center in Israel and intends to conduct its first- in-…
Los Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a…
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will…
Opus to advance preclinical development programs for BEST1– and RHO-related retinal diseases Deal expands Opus’…
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will…